| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8441656 | European Journal of Cancer | 2016 | 11 Pages |
Abstract
Ganetespib inhibits the growth of PC cells, an effect associated with downregulation of signalling through the JAK2-STAT3, PI3K/AKT and MAPK pathways. This provides preclinical proof-of-principle that ganetespib enhances the activity of chemotherapeutic agents and warrants further evaluation in PC clinical trials.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Ganji Purnachandra Nagaraju, Anya Mezina, Walid L. Shaib, Jerome Landry, Bassel F. El-Rayes,